HomeCompareLIAN vs SPHD

LIAN vs SPHD: Dividend Comparison 2026

LIAN yields 134.80% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LIAN wins by $14.69M in total portfolio value
10 years
LIAN
LIAN
● Live price
134.80%
Share price
$0.32
Annual div
$0.43
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14.72M
Annual income
$5,984,170.20
Full LIAN calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — LIAN vs SPHD

📍 LIAN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLIANSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LIAN + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LIAN pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LIAN
Annual income on $10K today (after 15% tax)
$11,457.68/yr
After 10yr DRIP, annual income (after tax)
$5,086,544.67/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, LIAN beats the other by $5,086,059.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LIAN + SPHD for your $10,000?

LIAN: 50%SPHD: 50%
100% SPHD50/50100% LIAN
Portfolio after 10yr
$7.37M
Annual income
$2,992,370.76/yr
Blended yield
40.59%
📊

Analyst Conviction Gap

Where Wall Street is split right now

LIAN
Analyst Ratings
1
Buy
1
Hold
1
Sell
Consensus: Buy
Altman Z
-2.4
Piotroski
2/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LIAN buys
0
SPHD buys
0
No recent congressional trades found for LIAN or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLIANSPHD
Forward yield134.80%4.33%
Annual dividend / share$0.43$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$14.72M$26.5K
Annual income after 10y$5,984,170.20$571.32
Total dividends collected$13.51M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: LIAN vs SPHD ($10,000, DRIP)

YearLIAN PortfolioLIAN Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$24,180$13,479.62$11,133$432.85+$13.0KLIAN
2$56,333$30,460.96$12,363$450.36+$44.0KLIAN
3$126,601$66,324.55$13,695$467.39+$112.9KLIAN
4$274,767$139,304.02$15,138$483.90+$259.6KLIAN
5$576,559$282,557.87$16,697$499.88+$559.9KLIAN
6$1,171,036$554,118.18$18,382$515.31+$1.15MLIAN
7$2,304,838$1,051,829.48$20,198$530.17+$2.28MLIAN
8$4,400,957$1,934,780.61$22,157$544.46+$4.38MLIAN
9$8,161,691$3,452,667.04$24,266$558.18+$8.14MLIAN
10$14,717,180$5,984,170.20$26,536$571.32+$14.69MLIAN

LIAN vs SPHD: Complete Analysis 2026

LIANStock

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Full LIAN Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this LIAN vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LIAN vs SCHDLIAN vs JEPILIAN vs OLIAN vs KOLIAN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.